Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$222.62 +0.5%	$211.58	$181.73 ▼ $244.81	$391.50B	0.32	5.02 million shs	5.94 million shs
ABT Abbott Laboratories	$90.64 +2.2%	$90.93	$81.97 ▼ $139.06	$154.45B	0.63	11.32 million shs	12.73 million shs
AZN Astrazeneca	$178.79 +0.9%	$188.26	$137.23 ▼ $212.71	$274.93B	0.25	1.91 million shs	1.90 million shs
LLY Eli Lilly and Company	$1,122.47 -0.6%	$1,006.08	$623.78 ▼ $1,182.73	$1.06T	0.53	3.15 million shs	2.26 million shs
NVO Novo Nordisk A/S	$43.59 -0.7%	$42.55	$35.12 ▼ $75.78	$196.10B	0.78	12.38 million shs	7.13 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.54%	-1.17%	+5.74%	+6.79%	+16.61%
ABT Abbott Laboratories	+2.11%	-0.69%	+7.28%	-16.40%	-32.36%
AZN Astrazeneca	+0.81%	-2.49%	-1.56%	-5.11%	+21.54%
LLY Eli Lilly and Company	-0.68%	-1.82%	+11.67%	+22.42%	+38.98%
NVO Novo Nordisk A/S	-0.59%	+3.27%	-2.50%	+16.33%	-43.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$222.62 +0.5%	$211.58	$181.73 ▼ $244.81	$391.50B	0.32	5.02 million shs	5.94 million shs
ABT Abbott Laboratories	$90.64 +2.2%	$90.93	$81.97 ▼ $139.06	$154.45B	0.63	11.32 million shs	12.73 million shs
AZN Astrazeneca	$178.79 +0.9%	$188.26	$137.23 ▼ $212.71	$274.93B	0.25	1.91 million shs	1.90 million shs
LLY Eli Lilly and Company	$1,122.47 -0.6%	$1,006.08	$623.78 ▼ $1,182.73	$1.06T	0.53	3.15 million shs	2.26 million shs
NVO Novo Nordisk A/S	$43.59 -0.7%	$42.55	$35.12 ▼ $75.78	$196.10B	0.78	12.38 million shs	7.13 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.54%	-1.17%	+5.74%	+6.79%	+16.61%
ABT Abbott Laboratories	+2.11%	-0.69%	+7.28%	-16.40%	-32.36%
AZN Astrazeneca	+0.81%	-2.49%	-1.56%	-5.11%	+21.54%
LLY Eli Lilly and Company	-0.68%	-1.82%	+11.67%	+22.42%	+38.98%
NVO Novo Nordisk A/S	-0.59%	+3.27%	-2.50%	+16.33%	-43.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$253.43	13.84% Upside
ABT Abbott Laboratories	2.88	Moderate Buy	$118.30	30.53% Upside
AZN Astrazeneca	2.85	Moderate Buy	$205.33	14.85% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.74	9.38% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	50.39% Upside

Current Analyst Ratings Breakdown

Latest ABBV, LLY, NVO, ABT, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/15/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/12/2026	ABT Abbott Laboratories	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$120.00 ➝ $102.00
6/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,330.00 ➝ $1,350.00
6/9/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/9/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
6/9/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/8/2026	ABBV AbbVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
6/8/2026	AZN Astrazeneca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
6/8/2026	LLY Eli Lilly and Company	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/5/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/1/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$62.82B	6.26	$15.22 per share	14.63	($1.83) per share	-121.65
ABT Abbott Laboratories	$44.33B	3.56	$7.15 per share	12.68	$30.35 per share	2.99
AZN Astrazeneca	$58.74B	4.72	$13.04 per share	13.71	$31.41 per share	5.69
LLY Eli Lilly and Company	$65.18B	16.22	$24.98 per share	44.93	$28.07 per share	39.99
NVO Novo Nordisk A/S	$46.80B	4.16	$4.65 per share	9.37	$6.58 per share	6.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$2.03	109.67	13.66	0.68	5.79%	-576.45%	13.39%	7/30/2026 (Estimated)
ABT Abbott Laboratories	$6.52B	$3.57	25.39	14.98	1.53	13.90%	17.62%	10.01%	7/16/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.66	26.85	17.00	1.54	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.87	25.17	1.23	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.23	12.75	3.92	37.23%	63.31%	22.19%	8/5/2026 (Estimated)

Latest ABBV, LLY, NVO, ABT, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/29/2026	Q1 2026	ABBV AbbVie	$2.59	$2.65	+$0.06	$0.39	$14.72 billion	$15.00 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/16/2026	Q1 2026	ABT Abbott Laboratories	$1.14	$1.15	+$0.01	$0.61	$10.99 billion	$11.16 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	3.11%	+6.80%	340.89%	53 Years
ABT Abbott Laboratories	$2.52	2.78%	+10.39%	70.59%	54 Years
AZN Astrazeneca	$4.34	2.43%	+2.30%	65.17%	N/A
LLY Eli Lilly and Company	$6.92	0.62%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	4.01%	+21.74%	41.08%	N/A

Latest ABBV, LLY, NVO, ABT, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/12/2026	ABT Abbott Laboratories	quarterly	$0.63	2.87%	7/15/2026	7/15/2026	8/17/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.80	0.68
ABT Abbott Laboratories	0.56	1.39	1.01
AZN Astrazeneca	0.52	0.91	0.71
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
AZN Astrazeneca	20.35%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
ABT Abbott Laboratories	0.46%
AZN Astrazeneca	N/A
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
ABT Abbott Laboratories	115,000	1.74 billion	1.73 billion	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

ABBV, LLY, NVO, ABT, and AZN Headlines

Recent News About These Companies

Peloton Wealth Strategists Has $3.11 Million Stock Position in Novo Nordisk A/S $NVO

3 hours ago | marketbeat.com

200,465 Shares in Novo Nordisk A/S $NVO Acquired by Opal Capital LLC

4 hours ago | marketbeat.com

Novo Nordisk A/S $NVO Shares Purchased by Bank Hapoalim BM

June 17 at 4:05 AM | marketbeat.com

Novo Nordisk A/S $NVO Shares Sold by BLKBRD Asset Management LP

June 17 at 3:55 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Given Average Rating of "Hold" by Brokerages

June 17 at 2:08 AM | americanbankingnews.com

Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of "Hold" from Brokerages

June 17 at 2:06 AM | marketbeat.com

Hackers Begin to Leak Novo Nordisk's Stolen Data

June 16 at 10:54 PM | healthcareinfosecurity.comH

Ozempic maker Novo Nordisk breach exposed patients’ clinical trial data

June 16 at 10:54 PM | yahoo.com

Hacking group claims major attack of Novo Nordisk and attempted $25 million extortion

June 16 at 10:54 PM | japantimes.co.jpJ

Novo Nordisk (NYSE:NVO) Discloses Clinical Trial Data Breach As GLP 1 Supply Strain Continues

June 16 at 10:54 PM | finance.yahoo.com

Novo Nordisk (CPSE:NOVO B) Prepares China Filing For Oral Wegovy Pill

June 16 at 5:53 PM | finance.yahoo.com

Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion

June 16 at 2:01 PM | reuters.com

Novo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)

June 16 at 12:52 PM | seekingalpha.com

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

June 16 at 12:52 PM | finance.yahoo.com

European Stocks Higher in Tuesday Trading; Markets Buoyed by US, Iran Peace Deal; Inflation Remains a Concern

June 16 at 12:52 PM | finance.yahoo.com

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

June 16 at 10:01 AM | zacks.com

Novo Nordisk to seek approval soon to sell Wegovy pill in China

June 16 at 7:52 AM | msn.com

Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO

June 16 at 2:00 AM | reuters.com

HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?

June 15 at 3:12 PM | stocktwits.comS

Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?

June 15 at 11:41 AM | zacks.com

Novo Nordisk A/S - share repurchase programme

June 15 at 10:11 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABBV, LLY, NVO, ABT, and AZN Company Descriptions

AbbVie NYSE:ABBV

$222.62 +1.03 (+0.47%)

Closing price 06/16/2026 03:59 PM Eastern

Extended Trading

$222.38 -0.25 (-0.11%)

As of 09:14 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$90.64 +1.97 (+2.22%)

Closing price 06/16/2026 03:59 PM Eastern

Extended Trading

$90.44 -0.20 (-0.22%)

As of 09:10 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Astrazeneca NYSE:AZN

$178.79 +1.52 (+0.86%)

Closing price 06/16/2026 03:59 PM Eastern

Extended Trading

$179.30 +0.50 (+0.28%)

As of 09:15 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Eli Lilly and Company NYSE:LLY

$1,122.47 -6.88 (-0.61%)

Closing price 06/16/2026 03:59 PM Eastern

Extended Trading

$1,120.71 -1.75 (-0.16%)

As of 09:15 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$43.59 -0.33 (-0.74%)

Closing price 06/16/2026 03:59 PM Eastern

Extended Trading

$45.09 +1.49 (+3.43%)

As of 09:15 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, LLY, NVO, ABT, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, LLY, NVO, ABT, and AZN Earnings

Compare Dividends

Latest ABBV, LLY, NVO, ABT, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, LLY, NVO, ABT, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, LLY, NVO, ABT, and AZN Company Descriptions

AbbVie NYSE:ABBV

Abbott Laboratories NYSE:ABT

Astrazeneca NYSE:AZN

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools